Results 111 to 120 of about 3,780 (219)

The "Wearing Off" Phenomenon for Rasagiline, Entacapone, Carbidopa, and Levodopa in the Setting of Parkinson's Disease. [PDF]

HCA Healthc J Med
Cromwell R, Um T.
europepmc   +1 more source

Retrospective analysis of multimorbidity, polypharmacy, and drug interactions on postoperative outcomes in oral squamous cell carcinoma patients. [PDF]

Clin Oral Investig
Schmitz A, Reichardt C, Gierth J, Richter M, Mrosk F, Alfertshofer M, Knoedler L, Doll C, Hausmann F, Lee M, Kleikamp B, Rendenbach C, Heiland M, Koerdt S.   +13 more
europepmc   +1 more source

Characterizing the time of day and year of falls in people with probable Parkinson's disease. [PDF]

Sci Rep
Peterson DS, Johansson L, Westerlind B, Lopes de Oliveira T, Finkel D.   +4 more
europepmc   +1 more source

Early Levodopa-Induced Motor Complications in RAB39B X-Linked Parkinsonism. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Mackels L, Aktan D, Depierreux F.
europepmc   +1 more source

Constructing a Personalized Treatment Rule for Initial Therapy in Early Parkinson's Disease. [PDF]

Pharmacotherapy
Brehm ZP, Schneider RB, Venuto CS, Smith G, Pham CT, McDermott MP, Ertefaie A.   +6 more
europepmc   +1 more source

[More about antiparkinson agents].

Psychiatria polska, 1982
openaire   +1 more source

Network based approach for drug target identification in early onset Parkinson's disease. [PDF]

Sci Rep
Dey A, Chakraborty M, Maulik U, Bandyopadhyay S.   +3 more
europepmc   +1 more source

The Treatment of Older Patients with Parkinson's Disease. [PDF]

Dtsch Arztebl Int
Djukic M, Yoshida-Stiksrud E, Nau R.
europepmc   +1 more source

Comparative Pharmacokinetic Assessment of Once-Daily Extended-Release and Twice-Daily Amantadine Formulations in Healthy Male Subjects Under Fasting Conditions. [PDF]

Clin Drug Investig
Kumar S, Gurule S, Khuroo A, Singh S, Tyagi A, Srivastava A, Bedi S, Devkare P, Dharmadhikari S, Khandhedia C.   +9 more
europepmc   +1 more source

Reply to: Partially Levodopa-Responsive Parkinsonism in a Carrier of a Novel Pathogenic CLTC Variant. [PDF]

Mov Disord Clin Pract
Nardecchia F, Martinelli S, Pollini L, Leuzzi V.   +3 more
europepmc   +1 more source